ECL1i, d(LGTFLKC), a novel, small peptide that specifically inhibits CCL2-dependent migration

Area of Science:

• Immunology
• Pharmacology
• Medicinal Chemistry

Background:

• CC chemokine receptor type 2 (CCR2) is a critical target in inflammatory diseases.
• Existing nonpeptidic CCR2 antagonists have not yet achieved clinical approval.
• There is a need for novel therapeutic agents targeting CCR2 signaling.

Purpose of the Study:

• To identify a short peptide exhibiting allosteric antagonism against human and mouse CCR2.
• To characterize the inhibitory potential and selectivity of the novel peptide.
• To evaluate the in vivo efficacy of the peptide in an inflammatory disease model.

Main Methods:

• Sequence analysis and 3-dimensional modeling were used to design the peptide.
• In vitro assays assessed inhibition of CC chemokine ligand type 2 (CCL2)-triggered chemotaxis.
• In vivo studies utilized experimental autoimmune encephalomyelitis (EAE) mouse model.

Main Results:

• A 7-d-amino acid peptide, ECL1i (d(LGTFLKC)), was identified as a potent and selective CCR2 inhibitor.
• ECL1i selectively inhibited CCL2-triggered chemotaxis (IC50, 2 µM) without affecting other CCL2-associated events.
• In vivo, ECL1i attenuated disease progression in a mouse model of multiple sclerosis.

Conclusions:

• ECL1i is the first identified allosteric inhibitor of CCR2 with functional selectivity.
• ECL1i represents a promising therapeutic candidate for inflammatory conditions.
• This selective inhibitor may advance understanding of CCR2 signaling pathways.